







# **Extracellular Matrix Degradation-Driven Accumulation of Cytotoxic and** Inflammatory Vδ1 T-cells in Modic Type 1 Changes

Jan Devan<sup>1,2</sup>, Irina Heggli<sup>1,2</sup>, Tamara Mengis<sup>1,2</sup>, Michaela Sandalova<sup>1,2</sup>, Dominick Burri<sup>3</sup>, Pamella Bitterli<sup>1,2</sup>, Nick Herger<sup>1,2</sup>, Danilo Menghini<sup>1,2</sup>, Phelipe Hatt<sup>1,2</sup>, Mazda Farshad<sup>4</sup>, Oliver Distler<sup>1</sup>, Stefan Dudli<sup>1,2</sup>


<sup>1</sup> Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland,

<sup>2</sup> Department of Physical Medicine and Rheumatology, Balgrist University Hospital, University of Zurich, Switzerland,

<sup>3</sup>Computational and Systems Biology, Biozentrum, University of Basel, Switzerland;

<sup>4</sup> Department of Orthopaedics, Balgrist University Hospital, University of Zurich, Switzerland

Background




#### Modic Type 1 changes (MC1)

- associate with pain and inflammation

Results 1 Cytotoxic proinflammatory TCRV51 cells accumulate in MC1

**Center of Experimental** 

Rheumatology



#### •Endplate damage


- always occurs with MC1
- Exposes the immune-privileged intervertebral disc (IVD) to immune cells of the bone marrow

## Aim


Reveal immune cell subsets accumulating in MC1, discover why they accumulate there and what functional consequences it might have for the surrounding tissue.

### Proposed disease model

- ECM degradation leads to the activation of monocytes and the induction of stressinduced molecules in bone marrow resident cells
- IL15 Production activated of by monocytes allows the proliferation of TCR  $V\delta 1^+$  cells. These T cells kill stressed cells and contribute to tissue damage



Results 2 TCRVo1 cells in MC1 can proliferate in response to IL15, which is produced by subset of myeloid cells enriched within the MC1 lesions



Comparison of NKp80 on TCRVδ1 cells and other T cells. E) Comparison of Granzyme B on selected T cell subsets. F) Comparison  $\mathbf{\vec{E}}$ of Interferon y on selected T cell subsets. G) Comparison of IFN-y in bone marrow plasma MC1 lesions and intrapatient controls

